Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.

@article{Glabbeke2005InitialAL,
  title={Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.},
  author={M van Glabbeke and Jaap Verweij and Paolo Giovanni Casali and Axel le Cesne and Peter Hohenberger and Isabelle Laure Ray-Coquard and Marcus Schlemmer and Allan T. van Oosterom and David Goldstein and Rafa{\"e}l Sciot and P. C. W. Hogendoorn and Michelle T Brown and Rossella Bertulli and Ian Judson},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2005},
  volume={23 24},
  pages={5795-804}
}
PURPOSE The aim of this study was to identify factors predicting initial and late resistance of GI stromal tumor (GIST) patients to imatinib and to document the dose-response relationship in the prognostic subgroups. This study is based on the European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group randomized trial comparing two doses of imatinib in advanced disease. PATIENTS AND METHODS Initial resistance was defined as… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 114 extracted citations

Similar Papers

Loading similar papers…